comparemela.com

Latest Breaking News On - Elixir health public relations - Page 13 : comparemela.com

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 Cingulate Inc. , a biopharmaceutical company utilizing its.

United statesKansas cityThomas daltonAnn childressShanej schafferMelyssa weibleMatt krepsExchange commissionPlatform technologyCingulate incSecurities exchangeBehavior medicine incDarrow associatesElixir health public relationsDrug administrationResults indicative

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

RESEARCH TRIANGLE PARK, N.C., June 06, 2023 Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced Pedmarqsi™– known as PEDMARK® in. | June 6, 2023

United statesLindsay roccoLandierw ototoxicityRobert andradeDrug administrationEuropean commission marketing authorizationFennec pharmaceuticalsFennec pharmaceuticals incTrends in pharmacological sciencesOregon healthScience universityElixir health public relationsClinical oncology groupEuropean commissionChildren oncology groupGlobenewswire inc

Tavanta Therapeutics Announces New Preclinical Data for its Cystic Fibrosis Candidate TAVT-135 at Two Prominent Scientific Conferences

~ Data support potential for TAVT-135 to address significant unmet needs in people with cystic fibrosis, including those who are ineligible for, o.

United statesLynne powellAndreas maetzelLindsay roccoInternational conference poster presentationCystic fibrosis foundationInternational conferenceEuropean cystic fibrosis foundationElixir health public relationsTopics in airwayEuropean cystic fibrosis societyAmerican thoracic societyThoracic societyBasic science conferenceChief executive officerChief medical officer

Zambon Presents Survey Results Showcasing Humanistic Impact of Bronchiolitis Obliterans Syndrome on Patients in the United States

/PRNewswire/ Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people s health and the quality of patients .

United statesPrnewswire zambonLindsay roccoShahidj siddiquiPaola castellaniOperations medical affairsAmerican thoracic societyZambon united states ltdElixir health public relationsBronchiolitis obliterans syndromeObliterans syndromeAmyotrophic lateral sclerosisMedical affairsUnited states media contactLung transplantLung transplantation

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor. | May 12, 2023

United statesDarren clineChristina tartagliaMichaelw kalbAdrian adamsMelyssa weibleImpel pharmaceuticals incAmerican academy of neurologyExchange commissionCincor pharma incElixir health public relationsImpel pharmaceuticalsCompany developmentsDevelopment rd expensesNet product revenueHost investor conference call today

vimarsana © 2020. All Rights Reserved.